Bayer to present rearmost exploration on real- world impact of menopause symptoms at IMS 2022
The REALISE study explored symptom burden and impact of menopause symptoms in women across multiple countries, and the views of their treating croakers
./ This study verified vasomotor symptoms( VMS) are considered the most common and distressing menopause symptoms but also showed a high burden of symptoms beyond VMS in menopausal women It highlights the need for increased mindfulness and operation around menopause symptoms beyond VMS to enhance the dialogue and participated decision- making
Bayer will present rearmost exploration on menopause symptoms at the forthcoming 18th World Congress by the International Menopause Society( IMS), which takes place from October 26 – 29, in Lisboa, Portugal. This data will include crucial findings from the REALISE study, pressing the need to broaden the mindfulness of the compass and impact on menopause beyond vasomotor symptoms( VMS; also appertained to as hot flashes) as women constantly witness a range of other symptoms including mood changes, sleep disturbance and vaginal blankness. It shows the significance to broaden the mindfulness and operation around menopause symptoms beyond VMS, and their impact in women’s lives to enhance dialogue and participated decision- timber.
As a leader in women’s healthcare, Bayer is devoted to broadening remedial choices and to increase mindfulness and education around menopause. As part of this commitment, the company is probing new approaches to broaden its menopause portfolio, to address an important unmet medical need in menopause operation as presently a vast maturity of women isn’t entering treatment for their menopause symptoms.
Bayer’s donations at the IMS 2022 are
·# 11559 Real- world evaluation of croaker
- reported symptoms and burden of vasomotor symptoms associated with menopause in the United States and Europe Kingsberg S, Schoof N, Saydam S, Caetano C( Speaker), Janssenswillen C, Small M, Harvey M, Moeller C, Banks V ·# 11560 Case and croaker
alignment on symptoms of menopause findings from the real- world REALISE study in the United States and Europe
Kingsberg S, Schoof N, Saydam S, Caetano C( Speaker), Janssenswillen C, Scott M, Lee L, Moeller C, Banks V The bill session will be held on October 27 h1850- 2015 CEST.
To view the complete objectifications, please visit IMS Congress Website. About Vasomotor Symptoms
Vasomotor symptoms( VMS; also appertained to as hot flashes) is a result from hyperactivation of the thermoregulatory pathway intermediated by hypertrophy of the KNDy neurons due to pullout of estradiol, which can affect from progressive reduction of ovarian function due to natural menopause or medical intervention by bilateral oophorectomy or endocrine remedy. VMS are reported by over to 80 of women at some point during the menopausal transition and the leading cause for seeking medical attention during this particular phase of a woman’s life. Over1/3 of women report severe symptoms, which can last 10 times or further after the last menstrual period, with applicable impact in quality of life.
Vasomotor symptoms can also be caused by endocrine remedy for treatment or forestallment of bone cancer impact quality of life and treatment adherence and can not presently be addressed as no treatment options are available. About Menopause
By 2030, the world population of women in the menopause phase is projected to increase to1.2 billion, with 47 million new entrants each time. Menopause is a natural phase in women’s lives, related to progressive decline of ovarian function, which generally occurs in women in their late 40s or early 50s. It can also be the result of surgical or medical treatment, for illustration for bone cancer. The decline in hormone product by the ovaries can lead to colorful symptoms, which can dramatically affect a woman’s health, quality of life, consumption of healthcare and work productivity. The most constantly reported and bothersome symptoms during the menopausal transition are VMS, sleep disturbances and mood changes. With increased life, menopause operation is of growing significance since this is a period where women are at the peak of their life’s exertion, tête-à-tête and professionally. For this reason, maintaining functional capability and good quality of life is extremely applicable from both a healthcare and socio- profitable perspective. About Women’s Healthcare at Bayer
Bayer is a leader in the area of women’s healthcare, with a long-standing commitment to delivering wisdom for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long- acting birth control styles as well as curatives for menopause operation and gynecological conditions. Bayer is also fastening on innovative options to address the unmet medical requirements of women worldwide. moment, Bayer’s exploration and development sweats concentrate on chancing new treatment options for menopause as well as gynecological conditions and include several composites in colorful stages ofpre-clinical and clinical development. Together, these systems reflect the company’s approach to exploration, which prioritizes targets and pathways with the eventuality to alter the way that gynecological conditions are treated. also, Bayer intends to give 100 million women in low- and-middle income countries by 2030 with access to family planning by fundingmulti-stakeholder aid programs and by icing the force of affordable ultramodern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations. About Bayer
Bayer is a global enterprise with core capabilities in the life wisdom fields of health care and nutrition. Its products and services are designed to help people and the earth thrive by supporting sweats to master the major challenges presented by a growing and growing global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and produce value through invention and growth. The Bayer brand stands for trust, trustability and quality throughout the world. In financial 2021, the Group employed around,000 people and had deals of44.1 billion euros. R&D charges before special particulars amounted to5.3 billion euros.